Diabetes mellitus (DM) is a major cardiovascular (CV) risk factor. General Framingham Risk Profile (GFRP) and World Health Organization/International Society of Hypertension (WHO/ISH) charts were used to assess CV risk in DM in Oman. The GFRP identified more patients with medium-risk DM; GFRP and WHO/ISH identified essentially equal numbers at very high risk. These were then used to evaluate statin usage in Oman, including economics. Google lists innumerable tools from organizations, hospitals, practitioners, magazines, societies, clinics, and medical associations. The GFRP and WHO/ISH calculations provided useful DM assessment of populations in Oman. Other major risk models are Adult Treatment Panel III, based on Framingham, and Reynolds Risk Score; the latter incorporates other factors such as family history, high-sensitivity C-reactive protein, and hemoglobin A 1c (in DM). These models are useful in assessing specific populations. Individual practitioners with limited time may just evaluate patients as low, medium, and high CV risk based on general knowledge and then treat.
A Specific Cardiovascular Risk Assessment in Diabetes Mellitus
In their study of cardiovascular (CV) risk assessment in patients with diabetes mellitus (DM), in Oman, Al-Lawati et al, assessed the results obtained with 2 different risk prediction protocols. 1 They used the General Framingham Risk Profile (GFRP) 2,3 and the World Health Organization/International Society of Hypertension (WHO/ISH) risk-prediction charts. 4 The authors studying the patients in Oman 1 found that in their population with DM, the WHO/ISH risk tool identified a higher proportion of patients at a CV-risk threshold of 10%. On the other hand, the GFRP identified a higher proportion of patients with increased CV risk defined as 10% to <20% and 20% to <30%. For the highest CV disease risk (30%), both assessment tools identified an essentially similar proportion of patients. A relevant economic use was made of risk-assessment tools by the same authors to evaluate the recommendation for statin usage in Oman. The importance of such assessments is well supported by studies by Alanbaei et al in patients with acute coronary syndrome (ACS), in the Gulf region of the Middle East, wherein they reported a high prevalence of DM and smoking in these patients with ACS. 5 Of similar relevance, Al-Rasadi et al in their Gulf Registry of Acute Coronary Events (Gulf RACE) study of patients with ACS found an increased prevalence of low levels of high-density lipoprotein cholesterol (HDL-C). 6 Two significant predictors of this low HDL-C were DM and smoking.
Guidelines published by the Joint British Societies (JBS) have given recommendations for primary coronary heart disease (CHD) prevention, based on an assessment of absolute CHD risk. 7 These guidelines state that statin treatment should be initiated when the 10-year CHD risk is >30%, and aspirin should be administered when the CHD risk is >15%. On the other hand, the National Institute for Clinical Excellence (NICE) guidelines, involving lipid management in type 2 DM patients, recommended that a statin be given for a 10-year CHD risk of >15%, thereby advocating a more widespread use of statins. 8 The United Kingdom Prospective Diabetes Study (UKPDS) risk engine involved complicated formulas and calculated the absolute risk in type 2 DM patients. This risk engine incorporated glycemia (assessed by hemoglobin A 1c [HbA 1c ], systolic blood pressure, and lipid levels as the risk factors), in addition to age, sex, ethnicity, tobacco abuse, and time since diagnosis of diabetes, as a first diabetes-specific CHD risk assessment tool. 9 Compared with the Framingham Risk Profile, the 10-year risk of CHD in patients with newly diagnosed DM appeared to be markedly increased in the highest risk DM patients with more elevated HbA 1c . Adding some controversy, the Heart Protection Study suggested that all patients with DM in the age range of 40 to 80 years with a total cholesterol of >3.5 mmol/L (135 mg/dL), should be treated with a statin, implying that CHD risk estimation is not necessary. 10 A comparison of the JBS-risk calculator and the UKPDS risk engine was reported by Song and Brown. 11 In 700 type 2 DM patients from 9 general practice databases in Scarborough, England, free of any history of CV disease and therefore eligible for primary prevention intervention, it was found that both risk methods of evaluation determined a high proportion of risk levels warranting primary CHD prevention. If NICE guidelines were followed, both JBS and UKPDS methods identified approximately 65% of these diabetic patients to be eligible for aspirin and statin therapy. Lowering the risk threshold for statin treatment had a small numerical impact on the entire population. An example is that the reduction in CHD risk threshold with UKPDS from 30% to 15% identified only an additional 0.5% of the total population eligible for statin treatment. 11 The current population of Oman as of July 2012 is estimated at 3 090 150. 12 Al-Shookri et al noted that the number of participants living with DM, in Oman in the year 2000 was 75 000 and is estimated to increase to 217 000 by the year 2025. 13 Generalizing the results of Song and Brown 11 to Oman, Al-Lawati et al, estimated an eligibility of 19 000 to 26 000 diabetic patients for primary prevention with a statin, requiring less than 0.5% of the total annual expenditure of the Omani Ministry of Health. 1 On the other hand, it was determined that this expense would rise to 4% to 5% of the budget if a branded statin were to be used. It was concluded that the prevalence of CV disease risk over 10 years is high among Omani patients with type 2 DM.
Brief Description of Some Notable CV Risk Profiles
Multiple CV disease risk profiles are in use and they are usually directed at risk assessment and recommendations for CV disease prevention. A review of such risk calculators and assessments on Google shows innumerable risk tools promulgated by individual organizations, hospitals, medical practices, news magazines, various societies, clinics, and medical associations. An attempt to summarize these is beyond the scope of this article. Al-Lawati et al 1 refer to the GFRP for primary care. 2 The traditional Framingham risk factors of age, hypertension, tobacco abuse, DM, total cholesterol, and HDL-C constitute the foundation for the Adult Treatment Panel III (ATP-III) CHD-risk prediction model. 14 In addition, other factors such as family history, high-sensitivity C-reactive protein (hsCRP), and HbA 1c in the diabetic patient also have a relationship to CV disease risk. These additional biomarkers have been made a part of the Reynolds Risk Score, which was developed in 2007 as an alternative expression for global risk in both women 15 and men (Table 1) . 16 
Utilization of CV Risk Profiles
How to use a CV risk profile, when to use one, and which one to select are problematic for many clinicians. There is much time pressure in most clinical practices to see as many patients as possible and little incentive to spend several minutes calculating a risk score for patients with CV disease. Both ATP-III, which incorporates traditional Framingham risk factors, and the Reynolds scores have been given class I recommendations by the American College of Cardiology and the American Heart Association. 17 In addition, both scores have been endorsed as part of the national guidelines for the prevention of CV disease in Canada. 18 The GFRP model of D'Agostino et al, for a CV disease risk profile for use in primary care, was derived from Framingham Heart Study patients. 2 A total of 8491 Framingham study participants, including 4522 women with age ranging from 30 to 74, attended a routine examination and were determined to be free of CV disease. Risk factors that were incorporated included age, total cholesterol, HDL-C, systolic blood pressure, treatment for hypertension, smoking, and status for DM. The CV events were classified as CHD, stroke, peripheral arterial disease (PAD), or congestive heart failure (CHF). Over a 12-year follow-up, 1174 participants, including 456 women, developed a first CV event. Two simple risk scores were presented, one of which was based on all traditional risk factors with the second using nonlaboratory factors as a basis. The results were sex-specific algorithms that could conveniently be used to evaluate general CV disease risk and the risk of individual CV events (CHD, stroke, PAD, and CHF). 2 The key question is what the busy primary care or specialist practitioner will do when faced with a time-pressured encounter with an individual patient. The reality of medical practice is that as they endeavor to do the best for their patients with the time they have, physicians and other practitioners will be familiar with one or more sets of risk guidelines. It is easy to quickly classify the general risk of a patient based on family history, patient history of CV disease events, habits, such as smoking, presence of diabetes, hypertension, and elevated plasma cholesterol. The patient easily can be visualized as having low, medium, or high CV risk, and a decision on lifestyle recommendations and the use of medications can be made. When assessing an entire population to make widespread recommendations and financial decisions, it is much more likely that the medical staff involved will utilize and reference a risk protocol, as was done by Al-Lawati et al in Oman. 1 In any event, the many wellthought out, researched, and referenced risk-prediction protocols available to physicians, other practitioners, planners, and researchers have major values in decision making. These values are implicit when such protocols are used precisely with populations or in general concept with individual patients.
Conclusions
The study by Al-Lawati et al 1 in Oman demonstrates the important use of CV disease risk protocols in patients with DM and indicates valuable information regarding the Omani population. This includes the experience that one tool, GFRP, identified a higher proportion of patients with DM in the 2 mid-ranges of CV disease risk assessed. For the highest CV disease risk, the GFRP tool and the WHO/ISH tool identified a similar proportion of DM patients at risk. The risk assessment then helped with some relevant financial decisions involving the general population with DM. The authors demonstrate how CV disease risk tools vary and how they can assist general patient care. This value also extends to individual patients in the physician's or practitioner's office on the front lines of medicine, although the specific use of such tools will be less precise and more in general concept.
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